


Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Original Research





Federica Giugliano ^{a,b}, Paolo A. Zucali ^{c,h}, Giulia Galli ^d, Zelmira Ballatore ^e, Chiara Corti ^{a,b}, Pamela T. Aliaga ^a, Jacopo Uliano ^{a,b}, Grazia Vivanet ^{a,b}, Giuseppe Curigliano ^{a,b}, Fabio Conforti ^f, Paola Queirolo ^f, Rossana Berardi ^e, Sara Manglaviti ^d, Giulia Apollonio ^d, Matteo Perrino ^c, Federica Borea ^h, Federica D'Antonio ^h, Marina C. Garassino ^{d,g}, Tommaso De Pas ^{f,*}

^a Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy

^b Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy

^c Department of Oncology, IRCCS, Humanitas Clinical and Research Center, Via Manzoni 56, 20089, Rozzano, Milan, Italy

^d Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

^e Department of Medical Oncology, Università Politecnica Delle Marche, AOU Ospedali Riuniti di Ancona, Italy

f Division of Medical Oncology for Melanoma, Sarcoma & Rare Tumours, European Institute of Oncology, IRCCS, Milan,

Italy

^g Thoracic Oncology Program, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA

^h Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy

Received 9 February 2022; accepted 15 February 2022 Available online 25 February 2022

KEYWORDS

Thymic epithelial tumours; COVID vaccine; Sars-Cov-2 Abstract *Background:* International guidelines recommend severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine for patients with cancer.

A substantial risk of developing vaccine-related autoimmune toxicities could be hypothesised for patients with thymic epithelial tumours (TETs) due to their high risk of autoimmune disorders (ADs). Moreover, a cross-reaction between SARS-CoV-2 spike protein antibodies and various tissue proteins has been shown, and antibodies against nucleoproteins showed

E-mail address: Tommaso.depas@ieo.it (T. De Pas).

https://doi.org/10.1016/j.ejca.2022.02.011 0959-8049/© 2022 Elsevier Ltd. All rights reserved.

^{*} Corresponding author: Division of Medical Oncology for Melanoma, Sarcoma & Rare tumours, European Institute of Oncology, IRCCS, Milan, Italy.

overlaps in the autoimmune cross-reaction with antibodies to spike protein. Due to the rarity of TETs, no data addressing this hypothesis are available.

Methods: Patients with TETs who received SARS-CoV-2 vaccine, treated in 4 referral centres of the Italian Collaborative Group for ThYmic MalignanciEs (TYME) network between February 2021 and September 2021, were interviewed through a standardised 15-items questionnaire in order to describe the safety of SARS-CoV-2 vaccine in patients affected by TETs. *Results:* Data from 245 doses of vaccine administered to 126 patients (41 = thymic carcinoma, 85 = thymoma; 38 with AD, of which 26 with active AD) were collected. Nine patients had a previous COVID-19-positive swab. No cases of AD reactivation or worsening of a pre-existing AD were seen in the study population. A new diagnosis of myasthenia gravis likely unrelated to the vaccine was made in two patients after the vaccination. Sixty-four patients (51%) experienced a total of 103 adverse events, all G1/G2, most commonly fatigue, new or worsening muscle pain and chills. None AE required patients' hospitalisation.

Conclusions: SARS-CoV-2 mRNA vaccines appear to be safe in patients with TET, even in case of active or pre-existing AD.

© 2022 Elsevier Ltd. All rights reserved.

1. Introduction

International guidelines recommend severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine for patients with cancer. A substantial risk of developing vaccine-related autoimmune toxicities could be hypothesised for patients with thymic epithelial tumours (TETs) due to their higher risk of autoimmune disorders (ADs) and to the anecdotally reported AD flares temporally associated with SARS-CoV-2 vaccine [1-5].

Moreover, a cross-reaction between SARS-CoV-2 spike protein antibodies and various tissue proteins has been shown, and antibodies against nucleoproteins showed overlaps in the autoimmune cross-reaction with antibodies to spike protein [6].

Due to the rarity of TETs and to the exclusion of patients with active cancer from most randomised COVID-19 vaccine clinical trials [7–9], no data addressing this hypothesis are available.

To address this issue, we interviewed patients with TETs through a standardised 15-item questionnaire, treated in 4 referral centres of the Italian Collaborative Group for ThYmic MalignanciEs (TYME) who received SARS-CoV-2 vaccine between February 2021 and September 2021 [10].

2. Materials and methods

2.1. Study population

All patients aged 18 years old or more with pathologically confirmed diagnosis of TET (any stage) who received at least one dose of SARS-CoV-2 vaccine were identified in 4 referral centres of TYME network.

Patients who received vaccines between February 2021 and September 2021 (minimum follow-up: 10 weeks) were interviewed through a standardised 15-item questionnaire (Table 1 and Table 2).

2.2. Data collection

The institutional review board of each institution granted permission for this study (R1454/21-IEO 1527). Patient adverse events (AEs) were classified according to CTCAE v.5.0; history, activity and symptoms exacerbation of AD were defined by the treating oncologist, after alternative diagnosis had been excluded, based on current clinical guidelines. A standardised questionnaire was used to collect patients' medical history and data about adverse events (AEs) (Table A. 1).

2.3. Statistical analysis

Primary outcomes were AE rate and incidence of new ADs or worsening of pre-existing AD in the examined population. Statistical analysis was performed using R Statistical Software (version 4.1.2; R Foundation for Statistical Computing, Vienna, Austria).

3. Results

3.1. Patient characteristics

The clinical features of 126 patients affected by TET are summarised in Tables 1 and 2. Thirty-eight (30%) were affected by AD, of which 26 (20%) were active at the time of vaccination. Namely, 23 patients (18%) were affected by myasthenia gravis (MG), of which 15 (12%) had active disease at the time of the interview.

Nine patients (7%) referred a positive swab for SARS-CoV-2 in the last 12 months (Table A. 2), of which 7 (5%) reported COVID-19 symptoms. Oxygen therapy and/or hospitalisation were required for 4 patients.

Overall, 245 doses of vaccine were administered to 126 patients. All patients received at least one dose of SARS-CoV-2 vaccine, and 118 (94%) completed the

Table 1

Baseline clinical features of 126 patients affected by thymic epithel	ial
tumours (TET) vaccinated against SARS-CoV-2.	

Gender 59 43 16 Male 67 41 26 Median age (range) 61 (21–89) 59 (21–89) 63 (42–81) Comorbidities Hypertension 40 24 16 Diabetes 5 5 0 COPD 5 4 1 Asma 3 2 1 Vaping or smocking 6 4 2 BMI > 30 9 6 3 Actual stage ^b I 1 0 IIA 2 2 0 11 0 0 11 1 0 IIB 3 2 1 1 0 0 11 1 0 0 11 1 0 11 1 0 11 1 0 11 1 0 11 1 0 11 1 0 11 1 0 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			Thymoma	Thymic carcinoma ^a
Male674126Median age (range)61 (21-89)59 (21-89)63 (42-81)Comorbidities596170Hypertension402416Diabetes5070COPD541Asma321Asma30963Actual stage ^b 110II101IIA220IIB3021III642IVA18135IVB552827NED41347Histological subtype ^b 30Type A-B880Type B323230Type B4/B214041Other330Type B3/B314140Type B3/B31518Not R022166Received systemic treatment23 <td>Gender</td> <td></td> <td>-</td> <td>-</td>	Gender		-	-
Median age (range)61 (21-89)59 (21-89)63 (42-81)Comorbidities402416Diabetes550COPD541Asma321Vaping or smocking642BMI > 30963Actual stage ^b 10IIA10IIA220IIB321III642IVA18135IVB552827NED41347Histological subtype ^b 10Type A-B880Type B1880Type B223230Type B32330Type B1/B2440Type B2/B314140Type B3/thymic carcinoma101Orcological treatment733Type B3/thymic carcinoma101Orcological treatment8830Previous radiotherapy784830Previous surgery on primary957124tumour1666Received systemic treatment ^C 885335Received systemic treatment ^C 885335Not R0221667Within three months191717 </td <td>Female</td> <td>59</td> <td>43</td> <td>16</td>	Female	59	43	16
Comorbidities 40 24 16 Hypertension 40 24 16 Diabetes 5 5 0 COPD 5 4 1 Asma 3 2 1 Vaping or smocking 6 4 2 BMI > 30 9 6 3 Actual stage ^b 1 0 0 IIA 2 2 0 IB 3 2 1 III 6 4 2 IVA 18 13 5 IVB 55 28 27 NED 41 34 7 Histological subtype ^b 7 7 Type A 3 3 0 Type B1 8 8 0 Type B2 21 21 0 Type B1/B2 4 4 0 Type B1/B2 4 4 0 Type B2/B3 14 14 0 Type B3/thymic carcinoma	Male	67	41	26
Comorbidities 40 24 16 Hypertension 40 24 16 Diabetes 5 5 0 COPD 5 4 1 Asma 3 2 1 Vaping or smocking 6 4 2 BMI > 30 9 6 3 Actual stage ^b 1 0 0 IIA 2 2 0 IB 3 2 1 III 6 4 2 IVA 18 13 5 IVB 55 28 27 NED 41 34 7 Histological subtype ^b 7 7 Type A 3 3 0 Type B1 8 8 0 Type B2 21 21 0 Type B1/B2 4 4 0 Type B1/B2 4 4 0 Type B2/B3 14 14 0 Type B3/thymic carcinoma		61 (21-89)	59 (21-89)	63 (42-81)
Hypertension402416Diabetes550COPD541Asma321Vaping or smocking642BMI > 30963Actual stage ^b 110IA220IB321III642IVA18135IVB552827NED41347Histological subtype ^b 77Type A330Type B1880Type B221210Type B323230Thymic carcinoma41041Other330Type B1/B2440Type B3/Lb214140Type B3/Lb314140Type B3/thymic carcinoma101Orcological treatment724tumour735518Not R022166Received systemic treatment ^c 885335Received systemic treatment ^c 885335Received systemic treatment ^c 885335Not R022166Received systemic treatment ^c 885335Within three months551917		· · · ·	· · · ·	· · · ·
Diabetes550COPD541Asma321Vaping or smocking642BMI > 30963Actual stage ^b 110IIA220IIB321III642IVA18135IVB552827NED41347Histological subtype ^b 71Type A-B880Type B1880Type B221210Type B323230Thymic carcinoma41041Other330Type B1/B2440Type B2/B314140Type B3/thymic carcinoma101Oncological treatment77Previous radiotherapy784830Previous surgery on primary957124tumour73551818Not R0221666Received systemic treatment*85335Received systemic treatment*85335within three months191717	Hypertension	40	24	16
Asma321Vaping or smocking642BMI > 30963Actual stage ^b 110IIA220IIB321III642IVA18135IVB552827NED41347Histological subtype ^b 77Type A330Type B1880Type B221210Type B323230Thymic carcinoma41041Other330Type B1/B2440Type B3/thymic carcinoma101Oncological treatment724tumour $R0$ 735518Not R022166Received systemic treatment 6853335Received systemic treatment 61917within three months1011	Diabetes	5	5	0
Vaping or smocking 6 4 2 BMI > 30 9 6 3 Actual stage ^b I 1 0 II 1 1 0 IIA 2 2 0 IIB 3 2 1 III 6 4 2 IVA 18 13 5 IVB 55 28 27 NED 41 34 7 Histological subtype ^b T Type A-B 8 Type A-B 8 8 0 Type B1 8 8 0 Type B3 23 23 0 Thymic carcinoma 41 0 41 Other 3 3 0 Type B1/B2 4 4 0 Type B2/B3 14 14 0 Type B3/thymic carcinoma 1 0 1 Oncological treatment T 13 1 Previous radiotherapy 78 48 30	COPD	5	4	1
Vaping or smocking 6 4 2 BMI > 30 9 6 3 Actual stage ^b I 1 0 II 1 1 0 IIA 2 2 0 IIB 3 2 1 III 6 4 2 IVA 18 13 5 IVB 55 28 27 NED 41 34 7 Histological subtype ^b T Type A-B 8 0 Type A-B 8 8 0 0 1 Other 3 3 0 1 0 1 Other 3 3 0 1 0 1 Other 3 3 0 1 0 1 Oppe B1/B2 4 4 0 1 0 1 Oppe B2/B3 14 14 0 1 0 1 0 1 Oppe B3/thymic carcinoma 1 0	Asma	3	2	1
BMI > 30 9 6 3 Actual stage ^b 1 1 0 II 1 1 0 IIA 2 2 0 IIB 3 2 1 III 6 4 2 IVA 18 13 5 IVB 55 28 27 NED 41 34 7 Histological subtype ^b 7 7 Type A 3 3 0 Type A-B 8 8 0 Type B1 8 8 0 Type B3 23 23 0 Thymic carcinoma 41 0 41 Other 3 3 0 Type B1/B2 4 4 0 Type B2/B3 14 14 0 Type B3/thymic carcinoma 1 0 1 Oncological treatment 7 24 1 R0 73 55 18 Not R0 22 </td <td>Vaping or smocking</td> <td>6</td> <td></td> <td>2</td>	Vaping or smocking	6		2
Actual stageI110IIA220IIB321III642IVA18135IVB552827NED41347Histological subtypeb77Type A330Type A-B880Type B1880Type B323230Thymic carcinoma41041Other330Type B1/B2440Type B2/B314140Previous radiotherapy784830Previous surgery on primary957124tumour735518Not R022166Received systemic treatment61917within three months191717		9	6	3
I110IIA220IIB321III642IVA18135IVB552827NED41347Histological subtype ^b 7Type A330Type A-B880Type B1880Type B221210Type B323230Type B1/B2440Type B1/B2440Type B1/B2433Oncological treatment7124Iumour735518Not R022166Received systemic treatment 361917within three months1017				
IIB 3 2 1 III 6 4 2 IVA 18 13 5 IVB 55 28 27 NED 41 34 7 Histological subtype ^b 7 7 Type A 3 3 0 Type A-B 8 8 0 Type B1 8 8 0 Type B3 23 23 0 Type B1/B2 4 4 0 Type B3/thymic carcinoma 1 0 1 Oncological treatment 7 24 1 Previous radiotherapy 78 48 30 Previous surgery on primary 95 71 24 tumour 7 24 1 6 Received systemic treatment 88 5	0	1	1	0
III642IVA18135IVB552827NED41347Histological subtypeb57Type A330Type A-B880Type B1880Type B323230Type B1/B2440Type B3/B314140Type B3/B314140Type B3/hymic carcinoma101Oncological treatment101Previous radiotherapy784830Previous surgery on primary957124tumour122166Received systemic treatment61917within three months11917	IIA	2	2	0
IVA18135IVB552827NED41347Histological subtypebType A330Type A-B880Type B1880Type B221210Type B323230Thymic carcinoma41041Other330Type B1/B2440Type B2/B314140Type B3/thymic carcinoma101Oncological treatment101Previous radiotherapy784830Previous surgery on primary957124tumour166Received systemic treatment85335Received systemic treatment61917within three months11917	IIB	3	2	1
IVB 55 28 27 NED 41 34 7 Histological subtype ^b 5 5 8 7 Type A 3 3 0 0 Type A-B 8 8 0 0 Type B1 8 8 0 0 Type B2 21 21 0 0 Type B3 23 23 0 0 Type B1/B2 4 4 0 0 Type B2/B3 14 14 0 1 Oncological treatment 0 1 0 1 Previous radiotherapy 78 48 30 Previous surgery on primary 95 71 24 tumour 1 0 1 14 R0 73 55 18 18 Not R0 22 16 6 6 Received systemic treatment ⁶ 88 53 35 17 within three months 17 17 17 17	III	6	4	2
NED41347Histological subtypeType A330Type A-B880Type B1880Type B221210Type B323230Thymic carcinoma41041Other330Type B1/B2440Type B2/B314140Type B3/thymic carcinoma101Oncological treatmentPrevious radiotherapy784830Previous surgery on primary957124tumour122166Received systemic treatment85335Received systemic treatment351917within three months1917	IVA	18	13	5
Histological subtypeType A330Type A-B880Type B1880Type B221210Type B323230Thymic carcinoma41041Other330Type B1/B2440Type B2/B314140Type B3/thymic carcinoma101Oncological treatment101Previous radiotherapy784830Previous surgery on primary957124tumour122166Received systemic treatment885335Received systemic treatment 361917within three months11917	IVB	55	28	27
Type A 3 3 0 Type A-B 8 8 0 Type B1 8 8 0 Type B2 21 21 0 Type B3 23 23 0 Thymic carcinoma 41 0 41 Other 3 3 0 Type B1/B2 4 4 0 Type B2/B3 14 14 0 Type B3/thymic carcinoma 1 0 1 Oncological treatment 78 48 30 Previous radiotherapy 78 48 30 Previous surgery on primary 95 71 24 tumour 73 55 18 Not R0 22 16 6 Received systemic treatment ⁶ 88 53 35 Received systemic treatment 36 19 17 within three months 9 17	NED	41	34	7
Type A-B880Type B1880Type B221210Type B323230Thymic carcinoma41041Other330Type B1/B2440Type B2/B314140Type B3/thymic carcinoma101Oncological treatmentPrevious radiotherapy784830Previous surgery on primary957124tumour122166Received systemic treatment61917within three months191717	Histological subtype ^b			
Type B1880Type B221210Type B323230Thymic carcinoma41041Other330Type B1/B2440Type B2/B314140Type B3/thymic carcinoma101Oncological treatmentPrevious radiotherapy784830Previous surgery on primary957124tumour122166Received systemic treatment885335Received systemic treatment 361917within three months11017	Type A	3	3	0
Type B1880Type B221210Type B323230Thymic carcinoma41041Other330Type B1/B2440Type B2/B314140Type B3/thymic carcinoma101Oncological treatmentPrevious radiotherapy784830Previous surgery on primary957124tumour122166Received systemic treatment885335Received systemic treatment 361917within three months11017	Type A-B	8	8	0
Type B3 23 23 0 Thymic carcinoma 41 0 41 Other 3 3 0 Type B1/B2 4 4 0 Type B2/B3 14 14 0 Type B3/thymic carcinoma 1 0 1 Oncological treatment		8	8	0
Thymic carcinoma41041Other330Type B1/B2440Type B2/B314140Type B3/thymic carcinoma101Oncological treatmentPrevious radiotherapy784830Previous surgery on primary957124tumour735518Not R022166Received systemic treatment3535Received systemic treatment 361917within three months17	Type B2	21	21	0
Other330Type B1/B2440Type B2/B314140Type B3/thymic carcinoma101Oncological treatmentPrevious radiotherapy784830Previous surgery on primary957124tumour735518Not R022166Received systemic treatment3535Received systemic treatment61917within three months1917	Type B3	23	23	0
Type B1/B2 4 4 0 Type B2/B3 14 14 0 Type B3/thymic carcinoma 1 0 1 Oncological treatment Previous radiotherapy 78 48 30 Previous surgery on primary 95 71 24 tumour 73 55 18 Not R0 22 16 6 Received systemic treatment ⁶ 88 53 35 Received systemic treatment 36 19 17 within three months 5 18 16	Thymic carcinoma	41	0	41
Type B2/B314140Type B2/B314140Type B3/thymic carcinoma101Oncological treatmentPrevious radiotherapy784830Previous radiotherapy784830Previous surgery on primary957124tumour22166Received systemic treatment885335Received systemic treatment 361917within three months11	Other	3	3	0
Type B3/thymic carcinoma101Oncological treatmentPrevious radiotherapy784830Previous surgery on primary957124tumour735518Not R022166Received systemic treatment361917within three months111	Type B1/B2	4	4	0
Type B3/thymic carcinoma101Oncological treatmentPrevious radiotherapy784830Previous surgery on primary957124tumour735518Not R022166Received systemic treatment361917within three months111	Type B2/B3	14	14	0
Previous radiotherapy784830Previous surgery on primary957124tumour735518Not R022166Received systemic treatment885335Received systemic treatment 361917within three months17		1	0	1
Previous surgery on primary957124tumourR0735518Not R022166Received systemic treatment885335Received systemic treatment 361917within three months17				
tumour R0 73 55 18 Not R0 22 16 6 Received systemic treatment ⁶ 88 53 35 Received systemic treatment 36 19 17 within three months	Previous radiotherapy	78	48	30
tumour R0 73 55 18 Not R0 22 16 6 Received systemic treatment ⁶ 88 53 35 Received systemic treatment 36 19 17 within three months	Previous surgery on primary	95	71	24
Not R022166Received systemic treatment885335Received systemic treatment361917within three months1717				
Received systemic treatment885335Received systemic treatment361917within three months1717	R0	73	55	18
Received systemic treatment 36 19 17 within three months	Not R0	22	16	6
Received systemic treatment 36 19 17 within three months	Received systemic treatment ^c	88	53	35
	-	36	19	17
administration of vaccine ^d	2			
	administration of vaccine ^d			

Key: TET: thymic epithelial tumour; BPCO: chronic obstructive pulmonary disease; BMI: body mass index; NED: no evidence of disease. ^a Includes also type B3/thymic carcinoma.

^b Stage at the time of vaccination, according AJCC Cancer Staging, VIII ed

^c For any stage, independently from time of vaccination

^d Either before or after.

cycle with the second dose. One patient received also a third dose (booster dose). One hundred twenty-one (96%) patients received an mRNA-based vaccination, namely COMIRNATY[®] (Pfizer) (n = 105) or SPIVAX[®] (Moderna) (n = 16) (Table A. 3).

3.2. AEs to SARS-CoV-2 vaccination

Sixty-four patients (50.7%, 95% CI 0.41%-0.59%) experienced an AE after administration of SARS-CoV-2 vaccines. A total of 103 AEs was observed after administration of SARS-CoV-2 vaccine (Table 3 and Fig. 1).

All reported AEs were grade 1 (G1) or G2. No G3, G4 and G5 AEs were observed. The most common G1 AEs were fatigue (n = 28; 27.1%, 95% CI 18.8%– 36.8%), new or worsening muscle pain (n = 21; 20%, 95% CI 13%-29.4%) and chills (n = 14; 13.5\%, 95\% CI, 7.6%–21.7%). Other G1 AE were fever (n = 8; 7%, 95%) CI 3.4%-14.7%), headache (n = 7; 6.8%, 95% CI 2.7%-13.5%), vomiting (n = 2; 1.9%, 95% CI 2.4%-6.8%), diarrhoea (n = 2; 1.9%, 95% CI 2.4% – 6.8%) and other (n = 7; 6.8%, 95% CI 2.7%-13.5%). The most common G2 event was fever (n = 2; 1.9%, 95% CI 2.4%-6.8%) and new or worsening muscle pain (n = 2, 1.9%, 95% CI 2.4%-6.8%). The majority (n = 100; 97%, 95% CI 91.7%-99.4%) of AEs started within 7 days from vaccination and last 1-3 days (n = 84; 81.5%, 95% CI 72.7%-88.5%). 17 AE required outpatient systemic pharmacologic intervention, namely fever (n = 6), fatigue (n = 2), chills (n = 2), muscle pain (n = 3), joint pain (n = 2), vomiting (n = 1) and other (n = 1). None of the patients were hospitalised due to AEs.

3.3. Autoimmune disease after SARS-CoV-2 vaccination

No cases of reactivation or worsening of a pre-existing AD were seen in the whole study population. Two cases of the new diagnosis of AD (MG) were observed after administration of SARS-CoV-2 vaccines (COM-IRNATY[®]), both likely unrelated to vaccine administration.

In the first case, diagnosis osf MG was made at the same time with the first evidence of a previously

Table 2	Та	ble	2
---------	----	-----	---

Characteristics of autoimmune disorders (ADs) in 126 patients affected by thymic epithelial tumours (TET) vaccinated against SAR
--

	Total number of patients affected	Currently active AD	Immunosuppressive treatment required	Steroids (at immunosuppressive dose)
Myasthenia gravis	23 (1)	15 (1)	18 (1)	7 (0)
Other AD	12 (5)	9 (4)	6 (3)	2 (0)
Myasthenia gravis + other AD	3 (0)	2 (0)	2 (0)	1 (0)
Total	38 (6)	26 (5)	26 (4)	10 (0)

Key: AD: Autoimmune Disorders; TET: Thymic Epithelial Tumour. In brackets, results for patients affected by thymic carcinoma are reported.

Table 3	
Incidence table adverse events (AE) to COVID vacc	ine in patients affected by thymic epithelial tumours.
C 1ª 0 b	

	Grade ^a		Onset ^b			Duration ^c		Systemic pharmacological	
	G1	G2	<7 day	8-14 days	>15 days	1-3 days	4-7 days	>7 days	intervention required
Fever	8 (2)	2 (1)	10 (3)	0 (0)	0 (0)	9 (3)	1 (0)	0 (0)	6 (3)
Fatigue	27 (10)	1 (0)	26 (8)	1(1)	1 (1)	22 (8)	2 (0)	4 (2)	2 (1)
Headache	7 (2)	1 (0)	8 (2)	0 (0)	0 (0)	7 (2)	1 (0)	0 (0)	0 (0)
Chills	14 (6)	0 (0)	14 (6)	0 (0)	0 (0)	13 (6)	1 (0)	0 (0)	2 (1)
Muscle pain	19 (5)	2 (1)	21 (6)	0 (0)	0 (0)	17 (6)	4 (0)	0 (0)	3 (2)
Joint pain	8 (3)	1 (0)	9 (3)	0 (0)	0 (0)	5 (3)	4 (0)	0 (0)	2 (0)
Vomiting	2 (1)	0 (0)	2 (1)	0 (0)	0 (0)	2 (1)	0 (0)	0 (0)	1 (0)
Diarrhoea	2 (0)	1 (0)	3 (0)	0 (0)	0 (0)	2 (0)	0 (0)	0 (0)	0 (0)
Other	7 (0)	1 (0)	7 (0)	1 (0)	0 (0)	6 (0)	1 (0)	1 (0)	1 (0)

Note: 'Muscle pain' refers to new or worsening muscle pain; 'joint pain' refers to new or worsening joint pain. Results for patients affected by thymic carcinoma are reported in brackets.

Keys: ^a Grade of AE, according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

^b Days from vaccination to onset of AE.


^c Duration of AE.

unappreciated thymoma B2, three months after the second dose of vaccine.

The second patient was affected by thymic carcinoma and has had a negative testing for acetylcholine receptor antibodies (AChR-Ab) assessed in 2018. Tumour relapsed 2 years after surgery and the patient received systemic chemotherapy (last cycle on January 2021). In May 2021, just one day after the 1st vaccine administration, the patient reported the onset of asthenia and hyposthenia, and a switch-on of AChR-Ab test was found. Symptoms resolved spontaneously in less than three weeks, in the absence of specific treatments.

4. Discussion

Our results suggest that currently available SARS-CoV-2 mRNA vaccines could be safely administered in patients with TETs, even in case of active or pre-existing AD.






Fig. 1. Incidence of adverse events (AEs) to COVID vaccine in patients affected by thymic epithelial tumours. A: Grade of AE, according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. B: Days from vaccination to onset of AE. C: Duration of AE. Note: 'Muscle pain' refers to new or worsening muscle pain; 'joint pain' refers to new or worsening joint pain.

No G3-G4 toxicities have been captured in 245 vaccine administrations and no unexpected side effects have been observed, also in the subset of patients with a previous diagnosis of COVID-19. The rate and the spectrum of G1/G2-reported AE was consistent with those reported in the general population [7-9].

Two cases of newly diagnosed MG have been observed.

Several elements suggest the absence of a cause—effect relationship between vaccination and MG in both patients. The first one had a MG diagnosis in concomitance with the first evidence of a previously unappreciated thymoma; the other patient had a switch-on of AChR-Ab test just one day after the 1st vaccine administration, few months after a systemic tumour relapse.

Notably, despite the potential high risk of SARS-CoV-2 vaccines' autoimmune toxicity in patients with TETs, no patients experienced vaccine-related severe immune AE. This observation is particularly relevant considering that 38 patients have had a diagnosis of AD, even with active symptoms at the time of vaccine administration.

These data can be helpful to more confidently support and recommend SARS-CoV-2 vaccine to patients with TET, according to the international guidelines for patients with cancer.

4.1. Limitations

The number of patients included in our analysis could be not adequate to capture infrequent immune-related vaccine AEs in patients with TETs. No data (only 5 patients) are available on non-mRNA vaccines.

5. Conclusions

SARS-CoV-2 mRNA vaccines are safe in patients with TET, even in case of active or pre-existing AD.

Conflict of interest statement

The authors declare the following financial interests/ personal relationships which may be considered as potential competing interests: Disclosure: PAZ declare Consulting or Advisory Role for Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sanofi.

MCG declares personal financial interests with the following organisations: AstraZeneca, MSD International GmbH, BMS, Boehringer Ingelheim Italia S.p.A, Celgene, Eli Lilly, Ignyta, Incyte, Inivata, MedImmune, Novartis, Pfizer, Roche, Takeda; she also declares institutional financial interests with the following organisations: Eli Lilly, MSD, Pfizer (MISP), AstraZeneca, MSD International GmbH, BMS, Boehringer Ingelheim Italia S.p.A, Celgene, Ignyta, Incyte, Inivata, MedImmune, Novartis, Pfizer, Roche, Takeda, Tiziana, Foundation Medicine; she has received research funding from the following organisations: AIRC, AIFA, Italian Moh, TRANSCAN.

GMC declares personal fees from MSD, AstraZeneca, Eli Lilly and BMS, outside the submitted work.

RB is a consultant/advisory board member for Astra Zeneca, Boehringer Ingelheim, Novartis, MSD, Otsuka, Eli-Lilly, Roche.

PQ reports advisory board relationships at Roche, Novartis, MSD, BMS, Sun Pharma, Sanofi and Pierre Fabre.

GC has received personal fees from Ellipses Pharma, Roche, Pfizer, Novartis, Eli Lilly, Foundation Medicine, Bristol–Myers Squibb, Samsung, and Daiichi Sankyo outside the submitted work.

The remaining authors declare nothing to disclose.

CRediT statement

Federica Giuglian: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Software; Supervision; Validation; Visualization; Roles/Writing-original draft; Writing-review & editing. Paolo Andrea Zucali: Data curation; Formal analysis; Investigation, Validation; Visualization; Writing—review & editing. Giulia Galli: Data curation; Formal analysis; Investigation, Validation; Visualization; Writing-review & editing, Zelmira Ballatore: Data curation; Formal analysis; Investigation, Validation; Visualization; Writing-review & editing, Chiara Corti: Data curation; Validation; Roles/Writing-original draft; Writing-review & editing, Pamela Trillo: Aliaga: Data curation; Formal analysis; Investigation; Methodology; Writing-review & editing, Jacopo Uliano: Data curation; Formal analysis; Investigation; Methodology; Writing-review & editing, Grazia Vivanet: Data curation; Formal analysis; Investigation; Methodology; Writing-review & editing, Giuseppe Curigliano: Validation; Visualization, Writing-review & editing, Fabio Conforti: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing-original draft; Writing-review & editing, Paola Queirolo: Validation; Visualization, Writing-review & editing, Rossana Berardi: Data curation; Formal analysis; Investigation, Validation; Visualization; Roles/Writing-original draft; Writing-review & editing, Sara Manglaviti: Data curation; Formal analysis; Investigation, Validation; Visualization; Roles/Writing-original draft; Writing-review & editing, Giulia Apollonio: Data curation; Formal analysis; Investigation, Validation; Visualization; Writing-review & editing, Matteo Perrino: Data curation; Formal analysis; Investigation, Validation; Visualization; Writing-review & editing, Federica Borea: Data curation; Formal analysis;

Investigation, Validation; Visualization; Writing—review & editing, Federica D'Antonio: Data curation; Formal analysis; Investigation, Validation; Visualization; Writing—review & editing, Marina Chiara Garassino: Data curation; Formal analysis; Investigation, Validation; Visualization; Writing—review & editing, Tommaso De Pas: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing—original draft; Writing—review & editing.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial or not-forprofit sectors.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ejca.2022.02.011.

References

 Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010;5(10):S260-5. https://doi.org/ 10.1097/JTO.0b013e3181f1f62d.

- [2] Nakagiri T, Okumura M, Inoue M, et al. Thymoma-associated graft-versus-host disease-like erythroderma. J Thorac Oncol 2007; 2(12):1130–2. https://doi.org/10.1097/JTO.0b013e31815ba23a.
- [3] Tagliaferri AR, Narvaneni S, Azzam MH, Grist W. A case of COVID-19 vaccine causing a myasthenia gravis crisis. Cureus 2021. Published online June 10. https://doi.org/10.7759/cureus. 15581.
- [4] Soy M, Keser G, Atagunduz P, et al. A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review. Clin Rheumatol 2021;40(9):3533–45. https://doi.org/10. 1007/s10067-021-05700-z.
- [5] Capassoni M, Ketabchi S, Cassisa A, et al. AstraZeneca (AZD1222) COVID-19 vaccine-associated adverse drug event: a case report. J Med Virol 2021;93(10):5718-20. https://doi.org/ 10.1002/jmv.27175.
- [6] Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol 2021;11. https://doi.org/10.3389/fimmu.2020.617089.
- [7] Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) covid-19 vaccine. N Engl J Med 2021. Published online September 29. https://doi.org/ 10.1056/NEJMoa2105290.
- [8] Thomas SJ, Moreira ED, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine through 6 months. N Engl J Med 2021;385(19):1761-73. https://doi.org/10.1056/ NEJMoa2110345.
- [9] Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384(5):403–16. https://doi.org/10.1056/NEJMoa2035389.
- [10] TYME (ThyYmic MalignanciEs) network. https://urlsand.esvalabs. com/?u=http%3A/F/Fwww.tyme.eu&e=000823b1&h=a24ea583& f=y&p=n.